Basilea Pharmaceutica AG (BPMUF)
USD 52.83
(0.0%)
USD 52.83
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 23.24 Million CHF | 0.66% |
| 2022 | 23.04 Million CHF | 790.4% |
| 2021 | 2.11 Million CHF | 112.58% |
| 2020 | -5.88 Million CHF | -43.93% |
| 2019 | -14.31 Million CHF | 35.62% |
| 2018 | -22.24 Million CHF | -83.15% |
| 2017 | -10.36 Million CHF | 70.78% |
| 2016 | -41.57 Million CHF | 30.87% |
| 2015 | -59.15 Million CHF | -52.08% |
| 2014 | -39.53 Million CHF | -29.34% |
| 2013 | -30.57 Million CHF | 29.73% |
| 2012 | -47.2 Million CHF | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 5.07 Million CHF | 164.47% |
| 2024 Q2 | 5.07 Million CHF | 0.0% |
| 2023 Q1 | 19.46 Million CHF | -31.27% |
| 2023 Q4 | -15.96 Million CHF | -102.77% |
| 2023 Q3 | -7.87 Million CHF | -120.38% |
| 2023 Q2 | 38.65 Million CHF | 98.54% |
| 2023 FY | - CHF | 0.66% |
| 2022 Q1 | -4.26 Million CHF | -125.28% |
| 2022 Q4 | 28.32 Million CHF | 87.29% |
| 2022 Q3 | 15.12 Million CHF | 274.15% |
| 2022 Q2 | -8.68 Million CHF | -103.47% |
| 2022 FY | - CHF | 790.4% |
| 2021 Q2 | -14.95 Million CHF | -111.06% |
| 2021 Q4 | 16.88 Million CHF | 90.39% |
| 2021 FY | - CHF | 112.58% |
| 2021 Q1 | -7.08 Million CHF | 65.83% |
| 2021 Q3 | 8.86 Million CHF | 159.29% |
| 2020 FY | - CHF | -43.93% |
| 2020 Q1 | -271 Thousand CHF | 91.54% |
| 2020 Q4 | -20.73 Million CHF | -109.71% |
| 2020 Q2 | -1.32 Million CHF | -390.04% |
| 2020 Q3 | -9.88 Million CHF | -644.69% |
| 2019 FY | - CHF | 35.62% |
| 2019 Q4 | -3.2 Million CHF | -120.73% |
| 2019 Q1 | -5.61 Million CHF | -288.98% |
| 2019 Q3 | -1.45 Million CHF | 88.25% |
| 2019 Q2 | -12.35 Million CHF | -120.21% |
| 2018 FY | - CHF | -83.15% |
| 2018 Q3 | -1.44 Million CHF | 84.42% |
| 2018 Q2 | -9.26 Million CHF | 0.0% |
| 2018 Q1 | -9.26 Million CHF | -519.57% |
| 2018 Q4 | -1.44 Million CHF | 0.0% |
| 2017 Q1 | -8.32 Million CHF | 7.6% |
| 2017 Q4 | 2.2 Million CHF | 0.0% |
| 2017 FY | - CHF | 70.78% |
| 2017 Q2 | -8.32 Million CHF | 0.0% |
| 2017 Q3 | 2.2 Million CHF | 126.5% |
| 2016 Q2 | -11.82 Million CHF | 0.0% |
| 2016 Q3 | -9.01 Million CHF | 23.74% |
| 2016 Q4 | -9.01 Million CHF | 0.0% |
| 2016 FY | - CHF | 30.87% |
| 2016 Q1 | -11.82 Million CHF | 22.15% |
| 2015 FY | - CHF | -52.08% |
| 2015 Q3 | -15.18 Million CHF | -5.49% |
| 2015 Q2 | -14.39 Million CHF | 0.0% |
| 2015 Q1 | -14.39 Million CHF | -35.93% |
| 2015 Q4 | -15.18 Million CHF | 0.0% |
| 2014 Q2 | -9.17 Million CHF | 0.0% |
| 2014 FY | - CHF | -29.34% |
| 2014 Q4 | -10.59 Million CHF | 0.0% |
| 2014 Q3 | -10.59 Million CHF | -15.37% |
| 2014 Q1 | -9.17 Million CHF | -26.02% |
| 2013 Q3 | -7.05 Million CHF | 9.23% |
| 2013 FY | - CHF | 29.73% |
| 2013 Q4 | -7.28 Million CHF | -3.29% |
| 2013 Q2 | -7.76 Million CHF | 0.0% |
| 2013 Q1 | -7.76 Million CHF | -39.96% |
| 2012 FY | - CHF | 0.0% |
| 2012 Q3 | -5.74 Million CHF | 0.0% |
| 2012 Q4 | -5.55 Million CHF | 3.33% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 132.716% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 491.978% |
| SQZ Biotechnologies Company | -64.14 Million USD | 136.233% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 233.794% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 75.287% |
| Mesoblast Limited | -62.38 Million USD | 137.25% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 1612.973% |
| Genus plc | 73.7 Million USD | 68.467% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 451.508% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 755.202% |
| Marizyme, Inc. | -34.28 Million USD | 167.792% |
| ContraFect Corporation | -64.99 Million USD | 135.754% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 364.934% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 613.456% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 1757.859% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 978.822% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 1100.077% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 4586.088% |
| Accustem Sciences Inc. | -3.74 Million USD | 720.326% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 148.189% |
| EV Biologics, Inc. | -1.26 Million USD | 1934.063% |
| Q BioMed Inc. | -617.62 Thousand USD | 3862.783% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | -550.616% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 3774.854% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 1117.295% |
| Biomind Labs Inc. | -1.03 Million USD | 2346.389% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 9.87 Million USD | -135.294% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 424.523% |
| Skye Bioscience, Inc. | -13.54 Million USD | 271.544% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 1662.445% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 93060.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 698.303% |
| IMV Inc. | -35.52 Million USD | 165.422% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 246.442% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 1028.871% |
| GB Sciences, Inc. | -1.41 Million USD | 1736.752% |
| Alpha Cognition Inc. | -9.7 Million USD | 339.449% |
| HST Global, Inc. | -5303.00 USD | 438342.504% |
| CSL Limited | 4.78 Billion USD | 99.515% |
| Halberd Corporation | -74.27 Thousand USD | 31387.443% |
| Enzolytics Inc. | -2.12 Million USD | 1195.178% |
| Resverlogix Corp. | -11.74 Million USD | 297.922% |
| Affymax, Inc. | -14.29 Million USD | 262.574% |
| SYBLEU INC | -141.57 Thousand USD | 16515.791% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 858.729% |
| argenx SE | -216.02 Million USD | 110.758% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 141.996% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | -1809.614% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 1650.464% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | -6034.451% |
| AVAX Technologies, Inc. | -6.11 Million USD | 480.196% |
| Zenith Capital Corp. | -8.6 Million USD | 370.044% |
| Genscript Biotech Corporation | -248.71 Million USD | 109.344% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 133502.216% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 1049.944% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 13302.718% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 158.632% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 903.506% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 2321.135% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | -345527.603% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 1428.001% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 1309.843% |
| BioStem Technologies, Inc. | -7.55 Million USD | 407.666% |
| ONE Bio Corp. | 13.61 Million USD | -70.719% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 12933.539% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 1229.801% |
| Agentix Corp. | -1.37 Million USD | 1794.179% |
| LadRx Corporation | 412.28 Thousand USD | -5536.905% |
| Cell Source, Inc. | -4.27 Million USD | 643.941% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 6428.614% |
| Regen BioPharma, Inc. | 1.46 Million USD | -1485.314% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 2580.391% |
| NovAccess Global Inc. | -1.03 Million USD | 2345.851% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | -162.486% |
| Itoco Inc. | -1.86 Million USD | 1343.449% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 6221.911% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 2182.437% |
| Kadimastem Ltd | -2.62 Million USD | 985.542% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 9817.75% |
| CytoDyn Inc. | -18.02 Million USD | 228.903% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 29506.927% |
| Mobile Lads Corp. | -2.24 Million USD | 1136.963% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 190140.069% |
| Qrons Inc. | -40.08 Thousand USD | 58082.585% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 4885.063% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | -4306.247% |
| Rebus Holdings, Inc. | -951 Thousand USD | 2543.743% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 2288.303% |
| International Stem Cell Corporation | 202 Thousand USD | -11404.95% |
| Bioxytran, Inc. | -3.82 Million USD | 708.354% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 44248.936% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 1043.974% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 164.791% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -45 Thousand USD | 51744.444% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 948.795% |
| Neutra Corp. | -181.24 Thousand USD | 12922.281% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 215.283% |
| PureTech Health plc | -11.62 Million USD | 299.88% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 215.291% |
| IXICO plc | -707 Thousand USD | 3387.129% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 402.407% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 148.07% |
| CSL Limited | 4.73 Billion USD | 99.509% |
| Cellectis S.A. | -92.63 Million USD | 125.087% |